Acquisition Completed
Ligand Pharmaceuticals acquisition of XOMA Royalty
US$739m equity value
Announced 27 Apr 2026 · NASDAQ: XOMA · US$39.00 cash per share
Advisers
XOMA Royalty
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Ligand Pharmaceuticals Incorporated
Acquirer
- Legal adviser
- Communications
- Target
- XOMA Royalty
- Acquirer
- Ligand Pharmaceuticals Incorporated
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 14 Jul 2026
- Sector
- Specialty finance and leasing
- Tags
- Specialty finance and leasing, Biotech, Life Sciences
In the league tables
- M&A financial advisers, 2026 to date Citi #7 · Leerink Partners #27 · Stifel #51 · H.C. Wainwright & Co. #87
- M&A financial advisers, completed, 2026 to date Citi #5 · Leerink Partners #45 · Stifel #46 · H.C. Wainwright & Co. #56
- M&A legal advisers, 2026 to date Gibson Dunn #16 · Paul Hastings #33
- M&A legal advisers, completed, 2026 to date Gibson Dunn #11 · Paul Hastings #18
- Fairness opinion providers, 2026 to date Leerink Partners #25
Similar deals
- Royalty Pharma acquisition of PTC Therapeutics' remaining royalty on Roche's Evrysdi Jan 2026 · US$240m · Specialty finance and leasing
- BRUKER acquisition of MIMETAS Aug 2026 · Life Sciences
- Oberland Capital Management stake in MeiraGTx Holdings Jul 2026 · Biotech
- Eli Lilly and Company acquisition of Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program Jun 2026 · Biotech
- HealthCare Royalty acquisition of Modeyso commercial sales royalties Apr 2026 · Specialty finance and leasing
Sources
- 27 Apr 2026 Press release (EX-99.1, exhibit), Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s sec.gov
- 10 Jun 2026 Definitive merger proxy statement (DEFM14A), XOMA Royalty Corp sec.gov
- 14 Jul 2026 Press release (EX-99.1, exhibit), XOMA Royalty Announces Closing of Its Acquisition by Ligand sec.gov
- 14 Jul 2026 Press release (EX-99.1, exhibit), Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets sec.gov



